Compare General Motors Company (GM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Tango Therapeutics Inc. — how do they compare? General Motors Company trades at $83.17 (market cap $73.71B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: General Motors Company is far larger — about 19.7× Tango Therapeutics Inc.'s market cap, and General Motors Company pays a 0.86% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Tango Therapeutics Inc. for 0 Days on average.
| GM | TNGX | |
|---|---|---|
Market Cap | $73.71B | $3.75B |
Volume | 6,224,747 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $32.90 |
52-Week Low | $57.34 | $7.50 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $176.68B | $2.77B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $83.05, up 0.83% with a bullish technical signal. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, though Q3 2026 results are pending. Valuation metrics appear reasonable with P/S of 0.42 and P/B of 1.19, while profitability remains modest with 1.05% net margin. Recent news highlights competitive pressures as Toyota narrows the U.S. sales gap and Q3 vehicle sales declined 5.5%.
GM faces near-term headwinds from declining sales and margin pressure, but analyst consensus remains bullish with a $102.33 price target representing 23% upside. The company benefits from regulatory savings and EV partnerships, though execution risks and market share erosion require monitoring. Cash flow stability and dividend payments provide shareholder support amid industry transition challenges.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
